Adverum Biotechnologies, Inc.

Annahita Keravala

Mehdi Gasmi

Thomas W Chalberg, Jr

Christopher Chavez

Diana Cepeda

The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein that binds heparan sulfate proteoglycans, where the AAV virions exhibit greater infectivity of retinal cells, altered tropism and/or the ability to bind and cross the inner limiting membrane following intravitreal injection. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.

Modified AAV capsids and uses thereof

The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells.

Compositions and methods for enhanced gene expression

Provided are variant adeno-associated virus (AAV) capsid proteins and recombinant AAV virions having one or more variant AAV capsid proteins. Also provided are compositions and methods for the use of the recombinant AAV virions, such as for the treatment or prophylaxis of a disease or disorder.

Variant AAV capsids for intravitreal delivery

Provided are mutant viral capsid cell libraries, individual cells of such libraries, systems, vectors, and methods for generating the cell libraries, and methods of use thereof to screen for mutant viral capsids with desired characteristics.

Mutant viral capsid libraries and related systems and methods

The present disclosure provides polynucleotide cassettes, expression vectors, and methods for the expression of a gene in mammalian cells.

Growing community of inventors

Palo Alto, CA, United States of America

Annahita Keravala